Celldex Therapeutics, Inc.

Published Date: 05/06/2011
Category: Emerging Technologies & Scientific Research

Research Report Decription

Celldex Therapeutics, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on Celldex Therapeutics, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Celldex Therapeutics, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Celldex Therapeutics, Inc. including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Celldex Therapeutics, Inc.
• Intelligence on Celldex Therapeutics, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Celldex Therapeutics, Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Celldex Therapeutics, Inc. and the factors that influence its strategies 
• Track strategic initiatives of the company and latest corporate news and actions 
• Assess Celldex Therapeutics, Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Celldex Therapeutics, Inc.’s business structure, strategy and prospects

Companies Mentioned:

Celldex Therapeutics, Inc.

Paper Highlights:

Celldex Therapeutics (formerly known as Avant Immunotherapeutics) is a biotechnology company engaged in the discovery, development and commercialization of targeted immunotherapies. The company focuses on the use of tumor-specific targets and human monoclonal antibodies as precision delivered therapeutic agents for the treatment of cancer, infectious and inflammatory diseases. The company operates in the US and the UK. It is headquartered in Needham, Massachusetts and employed 90 people as of December 2009. The company recorded revenues of $15.2 million during the financial year (FY) ended December 2009, as compared to the revenues of $7.5 million in FY2008. The operating loss of the company was $36.9 million during FY2009, as compared to an operating loss of $48.8 million in FY2008. The net loss was $36.5 million in FY2009, as compared to a net loss of $47.5 million in FY2008.